Pancreatic Cancer Research

ResearcherUniversity of Southern CaliforniaActive in the last 2 years

Bo Han

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0003-1458-4265; OpenAlex author ID A5005638984; NIH RePORTER profile ID 10420785. Sources: OpenAlex.

Their work

Papers
12 (first author 0, last author 2)
Trials
0
Grants
1
Labs led
1
Collaborators
27
Papers, trials and grants by year

2020: 1 paper · 2021: none · 2022: 3 papers · 2023: 3 papers · 2024: 1 paper · 2025: 3 papers · 2026: 1 paper, 1 grant

Papers 12

  1. Dimensional Priming Reprograms Adipose-Derived Stromal Cells to Promote Pancreatic Cancer Progression. Co-author DOI 10.3390/cancers18030460↗
  2. Matrix stiffness influences drug resistance to gemcitabine analog and AZD 1775 combination in PDAC organoids. Last author DOI 10.1371/journal.pone.0326550↗
  3. ECM Stiffness-Induced Redox Signaling Enhances Stearoyl Gemcitabine Efficacy in Pancreatic Cancer. Last author DOI 10.3390/cancers17050870↗
  4. Cachexia in Pancreatic Cancer: New Insights to Impact Quality of Life and Survival. Co-author DOI 10.3390/nu17193064↗
  5. Development of novel pyrimidine nucleoside analogs as potential anticancer agents: Synthesis, characterization, and In-vitro evaluation against pancreatic canc… Co-author DOI 10.1016/j.ejps.2024.106754↗
  6. Review of genetic and pharmacogenetic differences in cytotoxic and targeted therapies for pancreatic cancer in African Americans. Co-author DOI 10.1016/j.jnma.2023.01.008↗
  7. Biological evaluation of novel gemcitabine analog in patient-derived xenograft models of pancreatic cancer. Co-author DOI 10.1186/s12885-023-10928-w↗
  8. Evaluation of Anticancer Activity of Zhubech, a New 5-FU Analog Liposomal Formulation, against Pancreatic Cancer. Co-author DOI 10.3390/ijms24054288↗
  9. Synthesis, characterization, and anticancer evaluation of 1,3-bistetrahydrofuran-2yl-5-FU as a potential agent for pancreatic cancer. Co-author DOI 10.1186/s12885-022-10449-y↗
  10. Application of modified gemcitabine-loaded solid lipid nanoparticle in the treatment of pancreatic cancer patient-derived xenograft model Co-author DOI 10.21203/rs.3.rs-1777458/v1↗
  11. Associations of Overall Survival with Geriatric Nutritional Risk Index in Patients with Advanced Pancreatic Cancer. Co-author DOI 10.3390/nu14183800↗
  12. Comparative study on contrast enhancement of Magnevist and Magnevist-loaded nanoparticles in pancreatic cancer PDX model monitored by MRI. Co-author DOI 10.1186/s12645-020-00061-9↗

Grants 1

  1. Community Outreach Core (COC) U54CA233465↗

Closest collaborators

The 25 strongest of 27 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Edward Agyare · 10 shared papers, 2020–2025 · strength 2.01
  2. Sherise Chantell Rogers · 5 shared papers, 2023–2025 · strength 1.10
  3. Esther Frimpong · 6 shared papers, 2022–2024 · strength 1.07
  4. Thomas D. Schmittgen · 1 shared paper, 1 shared grant, 2026 · strength 0.96
  5. Andriana Inkoom · 5 shared papers, 2022–2024 · strength 0.88
  6. Nkafu Bechem Ndemazie · 5 shared papers, 2022–2024 · strength 0.88
  7. Raviteja Bulusu · 5 shared papers, 2022–2024 · strength 0.88
  8. Saunjoo L. Yoon · 3 shared papers, 2022–2025 · strength 0.81
  9. Jose Gilberto Trevino · 4 shared papers, 2020–2023 · strength 0.61
  10. Enrique Israel Velazquez Villarreal · 1 shared grant, 2026 · strength 0.60
  11. Wendy Cozen · 1 shared grant, 2026 · strength 0.60
  12. Veronica Wendy Setiawan · 1 shared grant, 2026 · strength 0.60
  13. Bo Han · 1 shared grant, 2026 · strength 0.60
  14. Bodour Salhia · 1 shared grant, 2026 · strength 0.60
  15. Lourdes A. Baezconde-Garbanati · 1 shared grant, 2026 · strength 0.60
  16. Jennifer Tsui · 1 shared grant, 2026 · strength 0.60
  17. Ba X. Hoang · 2 shared papers, 2025–2026 · strength 0.59
  18. Jonathan Barajas · 2 shared papers, 2025 · strength 0.54
  19. Thomas J. George · 2 shared papers, 2022–2023 · strength 0.41
  20. Joy C. Okoro · 2 shared papers, 2023–2024 · strength 0.40
  21. Diana J. Wilkie · 1 shared paper, 2025 · strength 0.28
  22. Shuqing Zhao · 1 shared paper, 2025 · strength 0.24
  23. Enrique I. Velazquez-Villarreal · 1 shared paper, 2025 · strength 0.24
  24. Christina Grinstead · 1 shared paper, 2022 · strength 0.22
  25. John M. Allen · 1 shared paper, 2023 · strength 0.18

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.